GSK PLC (GLAXF) filings document foreign-issuer disclosures for a global biopharma company registered in England and Wales. The record centers on Form 6-K current reports furnished under the Exchange Act, including announcements on product collaborations, capital-return programs, annual general meeting voting results, remuneration matters, board elections, and transaction notifications involving American Depositary Shares.
The filings also describe GSK's securities framework, including ordinary shares and ADS instruments, share repurchases and treasury-share treatment, PDMR transaction reporting, and governance resolutions connected with annual reporting and shareholder approvals. Product-related reports identify bepirovirsen in chronic hepatitis B and outline regulatory, quality, pharmacovigilance, commercial access, and global medical-strategy responsibilities associated with collaboration arrangements.
GSK plc (GSK) reports awards of Ordinary Shares under its 2025 Share Value Plan. On September 8, 2026, Victoria Whyte, SVP & Company Secretary, received an award of 10,050 Ordinary Shares at a reference price of £17.9650 per share.
On the same date, Neil Falkingham, a person closely associated with Lynn Baxter (President, Europe), also received an award of 10,050 Ordinary Shares at a reference price of £17.9650 per share under the same plan.
GSK plc (GSK) reported that on September 8, 2026 it granted a conditional share award to Roanne Parry, Chief People Officer and Executive Committee member, under the GlaxoSmithKline 2017 Performance Share Plan. The award covers 85,714 Ordinary Shares of 31¼ pence each, with performance measured over the three financial years from January 1, 2026 to December 31, 2028. Vesting will depend on achievement against performance measures set by the Remuneration Committee, aligned with those of other 2026 Executive Committee awards, and any portion that does not vest at the end of the period will lapse. Dividends will accrue during the performance period but only vest in line with the final vesting outcome.
GSK plc (GSK) reported its share capital and voting rights position as at 31 August 2026. The issued share capital consisted of 4,316,302,379 Ordinary Shares of 31¼ pence each, of which 270,881,064 shares were held in treasury.
After excluding treasury shares, the total number of voting rights in GSK was 4,045,421,315. Shareholders may use this voting-rights figure as the denominator when assessing whether they must notify interests or changes in interests under the UK Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.
GSK plc (GSK) reported positive phase II results for its investigational mRNA seasonal influenza vaccine and plans to advance the optimised candidate FLUm3HA.b-3NA into a phase III efficacy trial starting in September 2026. In a 971‑adult phase II trial, the vaccine generated higher immune responses against all tested influenza strains than licensed standard‑dose and high‑dose inactivated flu vaccines in younger and older adults, and was generally well tolerated.
The vaccine is designed to target both haemagglutinin (HA) and neuraminidase (NA), the two primary influenza surface antigens, whereas licensed vaccines primarily target HA. The programme is part of GSK’s broader respiratory vaccines research, and the candidate has received US FDA Fast Track designation for the targeted age indication.
GSK plc (GSK) reports a transaction by senior management under its executive savings plan. Maya Martinez-Davis, President, acquired 9.221 notional American Depositary Shares (ADS) of GSK within her GSK Executive Supplemental Savings Plan account at a price of $51.7800 per ADS. The transaction took place on 24 August 2026 on the New York Stock Exchange (XNYS). The filing classifies this as an acquisition of notional ADS rather than a direct market trade.
GSK plc (GSK) reports transactions by President Maya Martinez-Davis in the company’s American Depositary Shares (ADS). On 20 August 2026, she sold 3,916 ADS on the New York Stock Exchange at an aggregated price of $52.1400 per ADS. On 21 August 2026, she sold a further 40,481 ADS at an aggregated price of $52.1437 per ADS, also on the NYSE.
GSK plc (GSK) reports that Japan’s Ministry of Health, Labour and Welfare has granted the first global approval for Hibsago (bepirovirsen), an antisense oligonucleotide, as a functional cure for chronic hepatitis B in adults meeting specific viral and prior-treatment criteria. This is described as the first and only functional cure treatment for chronic hepatitis B approved in Japan, where nearly one million people live with the disease and it contributes to about 4,000 deaths annually. The approval was accelerated by SENKU designation, which recognises innovative medicines with high unmet medical need, and is supported by phase III B-Well data showing a 19% functional cure rate versus 0% on placebo, with an acceptable safety profile. GSK is pursuing additional regulatory submissions for bepirovirsen globally, including in the US.
GSK plc (GSK) reports that the US FDA has accepted for priority review a supplemental Biologics License Application for Jemperli (dostarlimab) as monotherapy in previously untreated stage II and III dMMR/MSI-H locally advanced rectal cancer, with a PDUFA action date in February 2027.
The filing highlights phase II AZUR-1 registrational trial data in 154 patients, where dostarlimab monotherapy achieved a meaningful and sustained 12‑month clinical complete response rate with a safety profile consistent with prior experience across solid tumours. Patients received nine 500 mg intravenous infusions every three weeks over six months.
The submission was also accepted under Project Orbis and is eligible for expedited review under the US National Priority Voucher program, potentially enabling earlier decisions in the US and other participating countries. Jemperli is already a key PD-1-blocking antibody in GSK’s immuno-oncology pipeline but is not currently approved for locally advanced rectal cancer.
GSK plc (GSK) has a notice of proposed sale under Rule 144 filed for the account of officer Maria E Martinez. The notice covers up to 44,397 American Depositary Shares of GSK to be sold through Charles Schwab & Co. on or after 08/20/2026 on the NYSE. The shares were acquired in multiple transactions, including Share Value Plan vesting on 02/19/2025 and 02/09/2026, Performance Share Plan vesting on 02/13/2026, and several dividend reinvestments in 2025–2026.
GSK plc (GSK) reported several acquisitions of American Depositary Shares involving senior personnel through dividend reinvestment on plan accounts. Dr Hal Barron, a non-executive director, acquired 2,279.563 notional ADS in an Executive Supplemental Savings Plan and 73 ADS in a 401(k) plan. James Ford, SVP and Group General Counsel, acquired 53.890 notional ADS, and Maya Martinez-Davis, President, acquired 82.133 notional ADS. All transactions took place on 14 August 2026 on the New York Stock Exchange at a price of $49.5200 per ADS and resulted from the reinvestment of dividends in GSK-sponsored plans.